Deglycosylated bleomycin induces apoptosis in lymphoma cell via c-jun NH2-terminal kinase but not reactive oxygen species

Biochemical Pharmacology

Volumn 74, Issue 10, 2007, Pages 1445-1455

  Souhir, Brahim ^a   Laurent, Prévotat ^b,c   Sonia, Yatouji ^a   Delphine, Mérino ^b   Marion, Cortier ^b,c   Cédric, Rébé ^b   Olivier, Micheau ^b   Abderraouf, Kenani ^a   Ali, Bettaieb ^b,c  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c NONE

Author keywords

Apoptosis; Bleomycin; Death receptors; JNK; Lymphoma; ROS

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BLEOMYCIN; CASPASE; CYTOCHROME C; DEATH RECEPTOR 4; DEATH RECEPTOR 5; PROTEIN BAX; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL SURFACE; CELL VIABILITY; CHROMATIN CONDENSATION; CONTROLLED STUDY; CYTOTOXICITY; DEGLYCOSYLATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVATION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LUNG FIBROSIS; LYMPHOMA CELL; OLIGOMERIZATION; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BLEOMYCIN; CASPASES; DNA FRAGMENTATION; FAS LIGAND PROTEIN; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LYMPHOMA; REACTIVE OXYGEN SPECIES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; U937 CELLS;

EID: 35348904416     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.07.036     Document Type: Article

References (49)

1. Umezawa H., Maeda K., Takeuchi T., and Okami Y. New antibiotics, bleomycin A and B. J Antibiot (Tokyo) 19 (1966) 200-209
2. Chen J., and Stubbe J. Bleomycins: towards better therapeutics. Nat Rev Cancer 5 (2005) 102-112
3. Boggs S.S., Sartiano G.P., and DeMezza A. Minimal bone marrow damage in mice given bleomycin. Cancer Res 34 (1974) 1938-1942
4. Lehane D.E., Hurd E., and Lane M. The effects of bleomycin on immunocompetence in man. Cancer Res 35 (1975) 2724-2728
5. Bayer R.A., Gaynor E.R., and Fisher R.I. Bleomycin in non-Hodgkin's lymphoma. Semin Oncol 19 (1992) 46-52 [discussion 52-53]
6. Bonadonna G., De Lena M., Monfardini S., Bartoli C., Bajetta E., Beretta G., et al. Clinical trials with bleomycin in lymphomas and in solid tumors. Eur J Cancer 8 (1972) 205-215
7. Hamakawa H., Bao Y., Takarada M., and Tanioka H. Histological effects and predictive biomarkers of TPP induction chemotherapy for oral carcinoma. J Oral Pathol Med 27 (1998) 87-94
8. Levi J.A., Raghavan D., Harvey V., Thompson D., Sandeman T., Gill G., et al., Australasian Germ Cell Group. The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. J Clin Oncol 11 (1993) 1300-1305
9. Martin W.G., Ristow K.M., Habermann T.M., Colgan J.P., Witzig T.E., and Ansell S.M. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 23 (2005) 7614-7620
10. Sleijfer S. Bleomycin-induced pneumonitis. Chest 120 (2001) 617-624
11. Sausville E.A., Peisach J., and Horwitz S.B. Effect of chelating agents and metal ions on the degradation of DNA by bleomycin. Biochemistry 17 (1978) 2740-2746
12. Iqbal Z.M., Kohn K.W., Ewig R.A., and Fornace Jr. A.J. Single-strand scission and repair of DNA in mammalian cells by bleomycin. Cancer Res 36 (1976) 3834-3838
13. Moore C.W., Malcolm A.W., Tomkinson K.N., and Little J.B. Ultrarapid recovery from lethal effects of bleomycin and gamma-radiation in stationary-phase human diploid fibroblasts. Cancer Res 45 (1985) 1978-1981
14. Tounekti O., Kenani A., Foray N., Orlowski S., and Mir L.M. The ratio of single- to double-strand DNA breaks and their absolute values determine cell death pathway. Br J Cancer 84 (2001) 1272-1279
15. Lee V.Y., Schroedl C., Brunelle J.K., Buccellato L.J., Akinci O.I., Kaneto H., et al. Bleomycin induces alveolar epithelial cell death through JNK-dependent activation of the mitochondrial death pathway. Am J Physiol Lung Cell Mol Physiol 289 (2005) L521-L528
16. Wallach-Dayan S.B., Izbicki G., Cohen P.Y., Gerstl-Golan R., Fine A., and Breuer R. Bleomycin initiates apoptosis of lung epithelial cells by ROS but not by Fas/FasL pathway. Am J Physiol Lung Cell Mol Physiol 290 (2006) L790-L796
17. Yang L.C., Yang S.H., Tai K.W., Chou M.Y., and Yang J.J. MEK inhibition enhances bleomycin A5-induced apoptosis in an oral cancer cell line: signaling mechanisms and therapeutic opportunities. J Oral Pathol Med 33 (2004) 37-45
18. Gimonet D., Landais E., Bobichon H., Coninx P., and Liautaud-Roger F. Induction of apoptosis by bleomycin in p53-null HL-60 leukemia cells. Int J Oncol 24 (2004) 313-319
19. Kenani A., Bailly C., Helbecque N., Catteau J.P., Houssin R., Bernier J.L., et al. The role of the gulose-mannose part of bleomycin in activation of iron-molecular oxygen complexes. Biochem J 253 (1988) 497-504
20. Filomenko R., Prevotat L., Rebe C., Cortier M., Jeannin J.F., Solary E., et al. Caspase-10 involvement in cytotoxic drug-induced apoptosis of tumor cells. Oncogene (2006)
21. Decaudin D., Marzo I., Brenner C., and Kroemer G. Mitochondria in chemotherapy-induced apoptosis: a prospective novel target of cancer therapy (review). Int J Oncol 12 (1998) 141-152
22. Kluck R.M., Bossy-Wetzel E., Green D.R., and Newmeyer D.D. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275 (1997) 1132-1136
23. Perkins C., Kim C.N., Fang G., and Bhalla K.N. Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel- or etoposide-treated HL-60 cells. Cancer Res 58 (1998) 4561-4566
24. Fulda S., Meyer E., Friesen C., Susin S.A., Kroemer G., and Debatin K.M. Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene 20 (2001) 1063-1075
25. Lacour S., Hammann A., Wotawa A., Corcos L., Solary E., and Dimanche-Boitrel M.T. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res 61 (2001) 1645-1651
26. Micheau O., Solary E., Hammann A., and Dimanche-Boitrel M.T. Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J Biol Chem 274 (1999) 7987-7992
27. Green D.R. Apoptotic pathways: paper wraps stone blunts scissors. Cell 102 (2000) 1-4
28. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K.J., et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 17 (1998) 1675-1687
29. Schneider P. Production of recombinant TRAIL and TRAIL receptor: Fc chimeric proteins. Methods Enzymol 322 (2000) 325-345
30. Claessens Y.E., Park S., Dubart-Kupperschmitt A., Mariot V., Garrido C., Chretien S., et al. Rescue of early-stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant-negative form of FADD. Blood 105 (2005) 4035-4042
31. Rebe C., Cathelin S., Launay S., Filomenko R., Prevotat L., L'Ollivier C., et al. Caspase-8 prevents sustained activation of NF-{kappa}B in monocytes undergoing macrophagic differentiation. Blood (2006)
32. Aye M.T., Seguin J.A., and McBurney J.P. Erythroid and granulocytic colony growth in cultures supplemented with human serum lipoproteins. J Cell Physiol 99 (1979) 233-238
33. Millet A., Bettaieb A., Renaud F., Prevotat L., Hammann A., Solary E., et al. Influence of the nitric oxide donor glyceryl trinitrate on apoptotic pathways in human colon cancer cells. Gastroenterology 123 (2002) 235-246
34. Galvan L., Huang C.H., Prestayko A.W., Stout J.T., Evans J.E., and Crooke S.T. Inhibition of bleomycin-induced DNA breakage by superoxide dismutase. Cancer Res 41 (1981) 5103-5106
35. Gillissen A., and Nowak D. Characterization of N-acetylcysteine and ambroxol in anti-oxidant therapy. Respir Med 92 (1998) 609-623
36. Canellos G.P., Anderson J.R., Propert K.J., Nissen N., Cooper M.R., Henderson E.S., et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327 (1992) 1478-1484
37. Hagimoto N., Kuwano K., Nomoto Y., Kunitake R., and Hara N. Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Cell Mol Biol 16 (1997) 91-101
38. Duggan D.B., Petroni G.R., Johnson J.L., Glick J.H., Fisher R.I., Connors J.M., et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 21 (2003) 607-614
39. Hagiwara S.I., Ishii Y., and Kitamura S. Aerosolized administration of N-acetylcysteine attenuates lung fibrosis induced by bleomycin in mice. Am J Respir Crit Care Med 162 (2000) 225-231
40. Kenani A., Bailly C., Houssin R., and Henichard J.P. Comparative subcellular distribution of the copper complexes of bleomycin-A2 and deglycobleomycin-A2. Anticancer Drugs 5 (1994) 199-201
41. Sordet O., Rebe C., Dubrez-Daloz L., Boudard D., and Solary E. Intracellular redistribution of procaspases during TPA-induced differentiation of U937 human leukemic cells. Leukemia 16 (2002) 1569-1570
42. Saeki K., Kobayashi N., Inazawa Y., Zhang H., Nishitoh H., Ichijo H., et al. Oxidation-triggered c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein (MAP) kinase pathways for apoptosis in human leukaemic cells stimulated by epigallocatechin-3-gallate (EGCG): a distinct pathway from those of chemically induced and receptor-mediated apoptosis. Biochem J 368 (2002) 705-720
43. Lei K., Nimnual A., Zong W.X., Kennedy N.J., Flavell R.A., Thompson C.B., et al. The Bax subfamily of Bcl2-related proteins is essential for apoptotic signal transduction by c-Jun NH(2)-terminal kinase. Mol Cell Biol 22 (2002) 4929-4942
44. Tournier C., Hess P., Yang D.D., Xu J., Turner T.K., Nimnual A., et al. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 288 (2000) 870-874
45. Aoshiba K., Yasui S., Tamaoki J., and Nagai A. The Fas/Fas-ligand system is not required for bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 162 (2000) 695-700
46. Muller M., Wilder S., Bannasch D., Israeli D., Lehlbach K., Li-Weber M., et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 188 (1998) 2033-2045
47. Muller M., Strand S., Hug H., Heinemann E.M., Walczak H., Hofmann W.J., et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 99 (1997) 403-413
48. Kuwano K., Hagimoto N., Kawasaki M., Yatomi T., Nakamura N., Nagata S., et al. Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J Clin Invest 104 (1999) 13-19
49. Grassme H., Cremesti A., Kolesnick R., and Gulbins E. Ceramide-mediated clustering is required for CD95-DISC formation. Oncogene 22 (2003) 5457-5470